Table 3: Studies consisting of patients with mixture of relapsed and primary metastatic Ewing’s sarcoma (combined outcomes for all patients reported).

StudyAverage age (years)Total number of ptsES (number of pts)Number of HDCT patients (ES rel)ChemotherapyResponse (number of pts)HDCT (mg/m2; mg/kg)Source of stem cellEFSOS

Al-Faris et al. 2007, retrospective [29]12.545Total (45)
Relapsed (19)
6TC
ICE
V
D
RP.SAEtoposide (2400 mg/m2)
Cytoxan (60 mg/kg/dose)
Melphalan (180 mg/m2/dose)
PBSCAll pts: HDCT: 1.5 yr EFS 60%/3 yr EFS 39%
Without HDCT: 1.5 yr EFS 36%/3 yr EFS 32%
All pts: HDCT: 1.5 yr OS 70%/3 yr OS 59%
Without HDCT: 1.5 yr OS 44%/3 yr OS 34%

Fraser et al. 2006, prospective single arm [30]11.536Total (16)
Relapse (6)
5ICE
V
C
CR (3)
PR (3)
Melphalan (50 mg/m2)
Busulfan (4 mg/kg)
Thiotepa (250/m2)
PBSC
BSC
NLES family-1 yr OS 69%/3 yr. OS 54% (HDCT)

Pape et al. 1999, retrospective [31]NL3939
No information on rel pts
NLEVAIANLMelphalan (30 mg/m2)
Etoposide (1800 mg/m2)
PBSCNLAll pts: 3.5 yr OS 31% (HDCT)

Kavan et al. 1999, prospective single Arm [32]12.631Total (27)NLNLNLMelphalan (NL)
Etoposide (NL)
Carboplatin (NL)
TBI
NLNLAll pts: 1.5 yr OS 58% (HDCT)

Ladenstein et al. 1995, registry [33]1363Total (50)
Relapsed (24)
Relapsed EFT (31)
24VAC/VAD
IVA/IVAD
CR (24)G1:
M + V or E + C (NL)
G2:
M + B ± Cy(NL)
G3: (NL)
M + Ba + V
M + Ba + P
M + Ba + T
G4 (NL)
Th + V + I + Ci
G5 (NL)
M + V + TBI
M + C + TBI
M + Ci + TBI
PBSC
BSC
All pts: 5 yr-27%
Relapsed pts (EFT) ()-5 yr EFS 32%
Primary MET pts-5 yr EFS-21% (HDCT)
NL

TC: topotecan and cyclophosphamide, ICE: ifosfamide, carboplatin, and etoposide, EVAIA: etoposide, vincristine, adriamycin, ifosfamide, and actinomycin D, HDCT: high-dose chemotherapy, TBI: total body irradiation, CR: complete response, PR: partial response, PBSC: peripheral blood stem cell, BSC: bone marrow stem cell, EFS: event-free survival, OS: overall survival, NL: not listed, V: vincristine, E: etoposide, C: carboplatin, T: teneposide, I: ifosphamide, A: adriamycin, D: doxorubicin, M: melphalan, V: vincristine, B: busulfan, Cy: cyclophosphamide, Ba: bichloronitrosourea, P: procarbazine, Ci: cisplatin, A: adriamycin, ES: Ewing’s sarcoma, rel: relapsed, RP.SA: response present, specifics unavailable, RFS: relapse-free survival, and ES rel: patients with relapsed ES that got HDCT.